T-cell Engager Archives

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

GSK to pay Chimagen $300m upfront to develop autoimmune drug

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

by HealthQuill
October 30, 2024
0 Comments

About Us

Contact Info

Follow Us

GSK to pay Chimagen $300m upfront to develop autoimmune drug